MultiMedica for Companies

COVID-19 Test Offer for Companies

Our Division of Occupational Medicine with its 30 years of experience in the field of Health Surveillance, together with a strong root in Lombardy with 4 hospitals, is at the side of Companies and Workers with a wide range of services and diagnostic paths useful for prevention, surveillance, contrast and containment of the spread of the virus SARS-CoV-2 in the workplace, in order to

  • protect the health of the Collaborators of the Company and, consequently;
  • preserve the continuity of the Company’s business in the safest possible conditions;

in the interest of all the company’s Stakeholders: not only the Employees, their Families and the Company, but also Customers, Suppliers, Lenders and Shareholders.

The resumption and continuity of production activities is in fact fundamental for the country, and the epidemiological dimension of the contagion among workers is fundamental for economic recovery.

Thanks to the availability, among its facilities in Milan, of a sophisticated laboratory of microbiology and virology authorized by the Lombardy Region, our division of Occupational Medicine is able to provide in total autonomy and in a short time both at the MultiMedica facilities, and directly at the headquarters of the client companies, as well as in “service” mode, the full range of clinical services useful for the prevention of the spread of the SARS-CoV-2 virus:

The above-mentioned clinical services of Occupational Medicine are rendered in favour of the collaborators of a Company by Centro Medico Polispecialistico AIECS S.r.l. (a subsidiary of MultiMedica S.p.A.) on a solvency basis, at the Company’s expense.

MultiMedica is the fourth Italian private multi-specialist health group operating in Lombardy under accreditation with the National Health Service in the areas of (a) provision of health services, (b) research activities, and (c) teaching/training:

  • has gained significant experience in the diagnosis and treatment of SARS-CoV-2, with almost 1,000 cases treated (including clinical and follow-up) in the 3 hospitals in Lombardy of the group converted to coronavirus;
  • as an IRCCS, MultiMedica has always been at the forefront of research on the virus with clinical trials on populations, aimed at assessing the epidemiology of the infection in specific collective settings, including the Mustang Occupation project in partnership with the University of Milan-Bicocca: the first Italian study that has been involved in assessing the prevalence of antibodies in the population of workers;
  • Thanks to the availability “in house” of a sophisticated laboratory of microbiology and virology authorized by the Lombardy Region is able to guarantee in total autonomy and in a short time the entire process of analysis and reporting of tests (serological and swabs)

In the current context, where:

  • the results of the national survey of seroprevalence have shown a spread of infection of 2.5% of the Italian population (i.e. 6 times higher than the cases officially intercepted during the pandemic), with Lombardy that has recorded the peak with 7.5% of seroprevalence, and peaks of 24% and 19% in the provinces of Bergamo and Cremona;
  • realistic expectation of time to have a large-scale vaccine is 10/12 months;
  • there is a sharp increase in contagions as a result of increased mobility related to the holiday period and the attention of the authorities is focused on the timely identification and management of inevitable future micro-outbreaks (specific collective geographical, social, work)

only SCREENING (Tests and Swabs)timely, and repeated over time,constitutes the appropriate response,in the context of a balanced cost/benefit ratio,to theissue of prevention and containment of the virus in the specific setting of a community over the next 12 months.

Company screening (Tests and Swabs) repeated over time indirectly results in additional positive impacts in various areas of the company:

  • for employees (and therefore indirectly of their families) the program represents a benefit much sought after in this historical phase, even more so if the company opts for a mode of delivery of the service at its headquarters (there is no need to go to a hospital / medical center, places certainly not perceived as healthy in this period);
  • for the management and corporate bodies, in addition to representing an element of self-protection in terms of corporate responsibility, as a tool that transcends the safety protocols in force, it is a concrete tool to demonstrate in relations with stakeholders (supervisory bodies, auditing firms, customers, suppliers, lenders, shareholders, etc.. ) an active policy of protection/preservation of business continuity, as a suitable tool to promote the prevention of the so-called micro outbreaks.

.